Takeda Pharmaceutical reported a second-quarter net loss due to impairment losses on certain products and cut its net-profit forecast for the fiscal year ending March 2024.
Takeda Pharmaceutical reported a second-quarter net loss due to impairment losses on certain products and cut its net-profit forecast for the fiscal year ending March 2024.